University of Washington-Seattle Campus · PharmacologyHepatitis B Treatment Innovation Lab
Rodney J.Y. Ho · Seattle, Washington
Research Focus
Dr. Rodney Ho's lab at the University of Washington focuses on developing new antiviral treatments for hepatitis B virus (HBV) that can last longer and reduce the need for daily medication. They aim to create innovative injection-based therapies that will help patients manage their condition more effectively and avoid complications like liver cancer. The lab collaborates with other experts to translate these ideas into real-world solutions that can significantly improve patient care.
HBVlong-acting antiviralHIV co-infectionviral suppressionclinical translationdrug developmentdrug-lipid interactionpharmacokinetics
Research Aims
4AIM 01Identify lead and backup antiviral compositions for long-acting HBV therapy.
AIM 02Evaluate pharmacokinetic profiles of potential long-acting dosage forms.
AIM 03Determine user preference characteristics for HBV therapy.
AIM 04Verify antiviral activity in primate and woodchuck models.
Skills the Lab Values
molecular-level studiesin vivo pharmacokineticsdrug formulationclinical evaluationbiological assayssubcutaneous injectionstoxicokinetic studiesuser-centered researchantiviral therapy development
Output against the department
Publications223top 37% of dept.168th of 462
this lab
most publishedleast published
Citations6.6kbottom 46% of dept.249th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.